Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Work In Process (2016 - 2019)

Plus Therapeutics (PSTV) has disclosed Work In Process for 9 consecutive years, with $662000.0 as the latest value for Q1 2019.

  • On a quarterly basis, Work In Process rose 18.85% to $662000.0 in Q1 2019 year-over-year; TTM through Mar 2019 was $662000.0, a 18.85% increase, with the full-year FY2018 number at $555000.0, down 23.13% from a year prior.
  • Work In Process was $662000.0 for Q1 2019 at Plus Therapeutics, up from $555000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $1.4 million in Q1 2015 to a low of $418000.0 in Q3 2018.
  • A 5-year average of $876588.2 and a median of $839000.0 in 2017 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: surged 194.59% in 2015, then crashed 53.21% in 2018.
  • Plus Therapeutics' Work In Process stood at $816000.0 in 2015, then grew by 25.12% to $1.0 million in 2016, then dropped by 29.29% to $722000.0 in 2017, then decreased by 23.13% to $555000.0 in 2018, then grew by 19.28% to $662000.0 in 2019.
  • Per Business Quant, the three most recent readings for PSTV's Work In Process are $662000.0 (Q1 2019), $555000.0 (Q4 2018), and $418000.0 (Q3 2018).